Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297069 | 0.84 | WDR5 (0.49) | WDR5GAAALDH1A1NOTUMTP53 | |
| SCHEMBL7556698 | 0.84 | MRGPRX4 (0.38) | MAPT | |
| SCHEMBL11031303 | 0.82 | KMT2A (0.57) | GAAALDH1A1LMNAPOLBMAPT | |
| SCHEMBL1345641 | 0.80 | ALOX15 (0.57) | GAAALDH1A1LMNANPC1RAB9A | |
| SCHEMBL10655453 | 0.80 | WDR5 (0.57) | WDR5GAAALDH1A1NOTUMTP53 | |
| SCHEMBL10655455 | 0.80 | WDR5 (0.57) | WDR5GAAALDH1A1NOTUMTP53 | |
| SCHEMBL5575155 | 0.78 | KDM4E (0.63) | GAAALDH1A1TP53LMNAPOLB | |
| SCHEMBL27490939 | 0.77 | WDR5 (0.48) | WDR5GAAALDH1A1NOTUMTP53 | |
| SCHEMBL523934 | 0.77 | LMNA (0.64) | WDR5GAATP53ALOX12FKBP1A | |
| SCHEMBL29447016 | 0.77 | LMNA (0.64) | WDR5GAATP53ALOX12FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0930296-B2 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0639563-B1 | Use of fluprostenol isopropyl ester for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension | ALCON LAB INC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6680339-B2 | TOPICALS TO TREAT GLAUCOMA AND OCULAR HYPERTENSION | ALCON MANUFACTURING, LTD. | 2004-01-20 | — | — | US | disclosed |
| US-6649653-B1 | Glaucoma treatment | ALCON MANUFACTURING, LTD. | 2003-11-18 | — | — | US | disclosed |
| US-20020151587-A1 | 15-fluoro prostaglandins as acular hypotensives | ALCON RESEARCH, LTD. | 2002-10-17 | — | — | US | disclosed |
| EP-0930296-B1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-6353014-B1 | TREATMENT OF VISION DEFECTS WITH PROSTAGLANDINS | ALCON LABORATORIES, INC. | 2002-03-05 | — | — | US | disclosed |
| US-6353000-B1 | INTRAOCULAR HYPERTENSION TREATMENT | ALCON LABORATORIES, INC. | 2002-03-05 | — | — | US | disclosed |
| EP-0783308-B1 | USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA | ALCON LAB INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0938472-B1 | 15-FLUORO PROSTAGLANDINS AS OCULAR HYPOTENSIVES | ALCON LAB INC (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-0938472-A2 | 15-FLUORO PROSTAGLANDINS AS OCULAR HYPOTENSIVES | ALCON LABORATORIES, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998021181-A2 | 15-FLUORO PROSTAGLANDINS AS OCULAR HYPOTENSIVES | ALCON LABORATORIES, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| WO-1998020881-A1 | 15-KETAL PROSTAGLANDINS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | ALCON LABORATORIES, INC (US) | 1998-05-22 | — | — | WO | disclosed |
| WO-1998020880-A2 | 11-HALO PROSTAGLANDINS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | ALCON LABORATORIES, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-4338316-A | PROSTAGLANDIN F SERIES ANALOGUES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-07-06 | — | — | US | disclosed |
| EP-0010360-B1 | PROSTANE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-06-02 | — | — | EP | disclosed |
| US-4233454-A | Cyclopentane acetic acid derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-11-11 | — | — | US | disclosed |
| US-4204001-A | PROSTAGLANDINS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-05-20 | — | — | US | disclosed |
| US-4115580-A | PROSTAGLANDINS, LUTEOLYSIS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151587-A1 | 15-fluoro prostaglandins as acular hypotensives | PTGIS, PTGIR, PTGFR | WDR5 2841/4885GAA 3925/4885ALDH1A1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.